Every 8-K that Kailera Therapeutics, Inc. (KLRA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow KLRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KLRA filings page.
Kailera Therapeutics reported second quarter 2026 results alongside extensive pipeline updates in obesity treatments. For the quarter ended June 30, 2026, the company recorded a net loss of $111.3 million, wider than $28.9 million a year earlier, driven by substantially higher research and development and general and administrative expenses as multiple clinical programs advanced.
As of June 30, 2026, Kailera held $1,171.8 million in cash, cash equivalents and marketable securities, which it expects will fund operations into mid‑2028. The pipeline includes a global Phase 3 KaiNETIC program for ribupatide injection in obesity, a fully enrolled U.S. Phase 2b high‑dose ribupatide trial, an active IND for ribupatide oral with global Phase 3 initiation planned in the first half of 2027, ongoing global Phase 2 studies of oral GLP‑1 agonist KAI‑7535, and preparations to start a Phase 1 trial of tri‑agonist KAI‑4729 in 2026.
Kailera Therapeutics reported first-quarter 2026 results and detailed rapid progress across its obesity-focused pipeline. The company recorded a net loss of $78.9 million for the quarter, wider than $18.0 million a year earlier, as research and development spending grew to $70.9 million from $10.1 million with multiple new clinical trials underway.
As of March 31, 2026, Kailera had $581.9 million in cash, cash equivalents and marketable securities, and recently closed an initial public offering of 44,921,875 shares at $16.00 per share for gross proceeds of $718.8 million, which together are expected to fund operations into mid-2028. Clinically, oral ribupatide achieved up to 12.1% mean weight loss at Week 26 with 38.6% of participants losing at least 15% of body weight, while tri-agonist KAI-4729 showed up to 16.0% weight loss at Week 12 versus 5.4% with placebo.
Kailera Therapeutics, Inc. completed its initial public offering, selling 44,921,875 shares of common stock, including 5,859,375 additional shares purchased by the underwriters, at $16.00 per share. The IPO generated gross proceeds of $718.8 million before underwriting discounts and expenses.
In connection with the IPO, Kailera filed a new amended and restated certificate of incorporation and adopted amended and restated bylaws. These governance changes increase authorized common stock to 800,000,000 shares, authorize 10,000,000 shares of undesignated preferred stock, create a classified board with three-year staggered terms, limit director removal to for-cause by a two‑thirds stockholder vote, restrict stockholder written consents, and add Delaware and federal court exclusive forum provisions for specified disputes.